Dr Arnie Clarke > Gill Jennings & Every LLP > London, England > Lawyer Profile

Arnie works in the fields of pharmaceutical, medicinal, industrial, food and organic chemistry, with particular expertise in small molecule pharmaceutical chemistry, secondary formulation of pharmaceutical products, drug repurposing and industrial formulation chemistry.

Arnie is an oppositions and appeals specialist, having been involved in over 300 oppositions. He currently attends between 15 and 25 hearings per year at the EPO. He regularly deals with multi-party proceedings and has experience in handling and supporting contentious cases involving parallel proceedings in multiple jurisdictions.

He also acts as an expert witness on legal procedure at the EPO, having represented a number of clients in national litigation.

Arnie’s clients recognise his ability to untangle and articulate the complexities of contentious proceedings at the EPO, while developing effective attacking and defensive strategies. Arnie is straight-forward, and always provides actionable advice, not just a range of options.

Arnie has been involved in a number of leading cases at the EPO over the last couple of years. Of note, he led the opponent strategy to obtain revocation Bristol-Myers Squibb’s (BMS) European patent no. 1169038, which claimed the $1.6 billion a year anti-cancer drug dasatinib, aka Sprycel®. He has also obtained revocation of a series of key Biogen patents covering the $4 billion a year Tecfidera® multiple sclerosis drug.

His success statistics for final, non-appealable decisions before the EPO Opposition and Appeal Boards are significantly better compared to the average of the current UK Legal 500 Top Tier Firms, all European Firms, all UK Firms and all German Firms.